Vista Pharmaceuticals
Healthcare
524711 BSE
₹6.19
Close ·
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹6.19 −3.75 −37.7% 1Y
Start ₹9.94
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- −30.30%
- Debt to Equity
- 0.28
- EPS (TTM)
- −₹1.91
- Book Value
- ₹5.92
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 1.05
- ROE
- −29.50%
- Dividend Yield
- 0.00%
- EBITDA
- −₹14.62 Cr
- 52W High
- ₹10.10
- 52W Low
- ₹5.32
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
29 Poor
Data confidence 91/100
Category scores
- Quality
- 6
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 43
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 2
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 24
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 32
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Stock is trading at 0.98 times its book value
- Debtor days have improved from 347 to 21.6 days.
Weaknesses
4- Company has low interest coverage ratio.
- Promoter holding is low: 21.2%
- Company has a low return on equity of -17.1% over last 3 years.
- Promoter holding has decreased over last 3 years: -8.32%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Neutral | 6 | 7 | 6 |
| Oscillators | Neutral | 1 | 7 | 1 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Neutral
Bearish
1
Neutral
7
Bullish
1
Overall
Neutral
Bearish
6
Neutral
7
Bullish
6
Moving Averages
Neutral
Bearish
5
Neutral
0
Bullish
5
Key readings
- RSI (14)
- 50.95
- Neutral
- MACD (12,26,9)
- 0.01
- Bullish
- SMA (50)
- 6.11
- Bullish
- SMA (200)
- 6.97
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | −10.40% |
|---|---|
| 5Y | +37.97% |
| 3Y | +71.00% |
| 1Y | −50.00% |
| TTM | −60.41% |
Net profit
| 10Y | Turned to loss |
|---|---|
| 5Y | Loss widened by ₹10 Cr |
| 3Y | Loss widened by ₹6 Cr |
| 1Y | Loss widened by ₹7 Cr |
| TTM | Loss widened by ₹6.68 Cr |
Operating cash flow
| 10Y | Outflow widened by ₹2 Cr |
|---|---|
| 5Y | Outflow narrowed by ₹3 Cr |
| 3Y | Outflow widened by ₹2 Cr |
| 1Y | Outflow narrowed by ₹3 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −320.00 pp |
|---|---|
| 5Y | −100.00 pp |
| 3Y | +100.00 pp |
| 1Y | −260.00 pp |
| TTM | −324.74 pp |
Revenue by year
| Mar 2017 | ₹24.00 Cr |
|---|---|
| Mar 2018 | ₹29.00 Cr |
| Mar 2019 | ₹31.00 Cr |
| Mar 2020 | ₹23.00 Cr |
| Mar 2021 | ₹1.00 Cr |
| Mar 2022 | ₹0.00 Cr |
| Mar 2023 | ₹1.00 Cr |
| Mar 2024 | ₹10.00 Cr |
| Mar 2025 | ₹10.00 Cr |
| Mar 2026 | ₹5.00 Cr |
Net profit by year
| Mar 2017 | ₹1.00 Cr |
|---|---|
| Mar 2018 | ₹2.00 Cr |
| Mar 2019 | ₹1.00 Cr |
| Mar 2020 | −₹4.00 Cr |
| Mar 2021 | −₹2.00 Cr |
| Mar 2022 | −₹1.00 Cr |
| Mar 2023 | −₹6.00 Cr |
| Mar 2024 | −₹5.00 Cr |
| Mar 2025 | −₹5.00 Cr |
| Mar 2026 | −₹12.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.98 | 3.47 | 1.7 | 3.13 | 1.8 | 2.49 | 2.56 | 3.23 | 1.52 | 1.46 | 2.42 | 0 | 0 |
| Expenses | 2.9 | 4.64 | 3.44 | 2.87 | 2.58 | 3.32 | 4.08 | 4.14 | 2.63 | 4.89 | 5.42 | 7.06 | 0.84 |
| Operating Profit | −0.92 | −1.17 | −1.74 | 0.26 | −0.78 | −0.83 | −1.52 | −0.91 | −1.11 | −3.43 | −3 | −7.06 | −0.84 |
| OPM % | −46.46% | −33.72% | −102.35% | 8.31% | −43.33% | −33.33% | −59.38% | −28.17% | −73.03% | −234.93% | −123.97% | — | — |
| Other Income | 0.13 | 0.08 | 0.02 | 0.1 | 0.07 | 0.01 | 0.12 | 0.24 | 0 | 0.19 | 0.09 | 0.03 | 0.04 |
| Interest | 0.33 | 0.32 | 0.3 | 0.28 | 0.28 | 0.25 | 0.22 | 0.21 | 0.19 | 0.18 | 0.18 | 0.55 | 0.34 |
| Depreciation | 0.17 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.19 | 0.18 | 0.18 | 0.2 | 0.19 | 0.19 | 0.19 |
| PBT | −1.29 | −1.59 | −2.2 | −0.1 | −1.17 | −1.25 | −1.81 | −1.06 | −1.48 | −3.62 | −3.28 | −7.77 | −1.33 |
| Tax % | −25.58% | 27.04% | −25.91% | −190% | −26.5% | −22.4% | −26.52% | 40.57% | −12.84% | −28.45% | −29.27% | −24.58% | −25.56% |
| Net Profit | −0.95 | −2.02 | −1.63 | 0.09 | −0.86 | −0.97 | −1.32 | −1.5 | −1.29 | −2.59 | −2.32 | −5.86 | −0.99 |
| EPS (₹) | −0.26 | −0.55 | −0.44 | 0.02 | −0.23 | −0.26 | −0.36 | −0.41 | −0.21 | −0.42 | −0.38 | −0.95 | −0.16 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 15 | 24 | 29 | 31 | 23 | 1 | 0 | 1 | 10 | 10 | 5 | 4 |
| Expenses | 11 | 13 | 21 | 24 | 30 | 28 | 3 | 2 | 5 | 13 | 14 | 20 | 18 |
| Operating Profit | 3 | 3 | 3 | 5 | 1 | −5 | −2 | −1 | −4 | −3 | −4 | −15 | −14 |
| OPM % | 20% | 17% | 13% | 18% | 4% | −21% | −136% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −432% | −33% | −41% | −271% | −369% |
| Other Income | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | 1 | 1 | 1 | 3 | 1 | −4 | −4 | −3 | −6 | −5 | −5 | −16 | −16 |
| Tax % | −9% | 8% | −2% | 23% | 18% | −7% | −47% | −66% | −4% | −13% | −12% | −25% | — |
| Net Profit | 1 | 1 | 1 | 2 | 1 | −4 | −2 | −1 | −6 | −5 | −5 | −12 | −12 |
| EPS (₹) | 0.11 | 0.06 | 0.47 | 0.75 | 0.31 | −1.21 | −0.55 | −0.24 | −1.54 | −1.23 | −1.26 | −1.96 | −1.91 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 12 | 12 |
| Reserves | 5 | 6 | 11 | 26 | 30 | 24 | 25 | 28 | 29 | 31 | 33 | 24 |
| Borrowings | 4 | 8 | 11 | 11 | 11 | 15 | 11 | 13 | 10 | 8 | 7 | 10 |
| Other Liabilities | 8 | 7 | 14 | 10 | 6 | 6 | 9 | 8 | 9 | 10 | 7 | 9 |
| Total Liabilities | 23 | 26 | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
| Fixed Assets | 11 | 10 | 13 | 18 | 21 | 21 | 20 | 19 | 20 | 19 | 19 | 18 |
| CWIP | 0 | 0 | 2 | 7 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 12 | 16 | 26 | 28 | 24 | 22 | 24 | 27 | 27 | 29 | 31 | 26 |
| Total Assets | 23 | 26 | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −4 | −2 | 3 | −5 | 3 | 1 | −7 | −1 | −2 | −5 | −7 | −4 |
| Investing | 0 | 0 | −4 | −11 | −6 | −2 | 0 | 0 | −1 | −1 | 0 | −1 |
| Financing | 4 | 3 | 6 | 11 | 1 | 0 | 7 | 1 | 3 | 6 | 8 | 5 |
| Net Cash Flow | 0 | 0 | 5 | −4 | −1 | −1 | 0 | 0 | 0 | 0 | 1 | −1 |
| Free Cash Flow | −4 | −3 | −1 | −15 | −2 | −1 | −7 | −1 | −3 | −6 | −7 | −5 |
| CFO/OP | −131 | −89 | 84 | −86 | 299 | −17 | 390 | 78 | 64 | 149 | 163 | 30 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 300 | 231 | 136 | 137 | 98 | 165 | 624 | — | 4,106 | 515 | 505 | 22 |
| Inventory Days | 10 | 97 | 185 | 250 | 162 | 148 | 4,840 | — | 991 | 279 | 359 | 770 |
| Days Payable | 359 | 236 | 293 | 209 | 76 | 79 | 2,555 | — | 1,007 | 304 | 244 | 443 |
| Cash Conversion Cycle | −50 | 92 | 27 | 178 | 184 | 234 | 2,909 | — | 4,089 | 490 | 620 | 349 |
| Working Capital Days | −8 | 206 | 12 | 137 | 137 | 81 | 1,681 | — | 3,460 | 318 | 440 | −95 |
| ROCE % | 14% | 10% | 9% | 12% | 6% | −5% | −5% | −4% | −10% | −8% | −9% | −30% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vista Pharmaceuticals insights
61 extracted metrics across FY10–FY27.
Documents
- 14 Aug 2026
- 13 Feb 2026
- 17 Jul 2026
- 18 Jul 2025
- 14 Jul 2024
- 18 Sep 2023
- 8 Jul 2020
- General announcements 12 Sep 2026
- General announcements 15 Jul 2026
Frequently Asked Questions about Vista Pharmaceuticals
What does Vista Pharmaceuticals Ltd do?
Incorporated in 1992, Vista Pharmaceuticals Ltd manufactures and sells pharmaceutical, medical and veterinary preparations
Where is Vista Pharmaceuticals Ltd (VISTAPH) listed?
Vista Pharmaceuticals Ltd trades under code 524711 on the BSE.
Which sector does Vista Pharmaceuticals Ltd belong to?
Vista Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Vista Pharmaceuticals Ltd?
Over the last 52 weeks Vista Pharmaceuticals Ltd has traded between ₹5.32 and ₹10.1 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd reported a return on equity of -29.50%. Its debt-to-equity ratio is 0.28.
Company Information
Incorporated in 1992, Vista Pharmaceuticals Ltd manufactures and sells pharmaceutical, medical and veterinary preparations
Website vistapharmaceuticals.com
Face Value ₹2
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524711.md for Vista Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.